Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 10:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 645 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Process-level Clear all
Suspended No phase listed Observational Accepts healthy volunteers

Skin Characteristics of Parents of Food Allergic Pediatric Patients

NCT04198753
View directory record Official record
Conditions
Food Allergy in Children
Interventions
Skin tape stripping, Skin barrier assessment, Blood draw
Diagnostic Test · Device
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 13, 2020 · Synced Oct 19, 2026, 10:46 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Allogeneic Human Mesenchymal Stem Cell Injection in PAtieNts With FaceTogenic Back Pain

NCT03487731
View directory record Official record
Conditions
Facetogenic Back Pain, Back Pain
Interventions
Allogeneic Human Mesenchymal Stem Cells (hMSCs), Placebo
Biological · Drug
Lead sponsor
Joshua M Hare
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 20, 2020 · Synced Oct 19, 2026, 10:46 PM EDT
Terminated Phase 2 Interventional Results available

Planned Donor Lymphocyte Infusion (DLI) After Allogeneic Stem Cell Transplantation (SCT)

NCT01518153
View directory record Official record
Conditions
Leukemia, Lymphoma, Myeloma, Myeloproliferative Diseases
Interventions
Fludarabine, Melphalan, Alemtuzumab, Stem Cell Infusion, Tacrolimus, Methotrexate, G-CSF, Low Dose Donor T-Cells, High Dose Donor T-Cells
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 17, 2016 · Synced Oct 19, 2026, 10:46 PM EDT
Terminated Phase 2 Interventional Results available

Reduced-Intensity Regimen Before Allogeneic Transplant for Patients With Relapsed Non-Hodgkin's or Hodgkin's Lymphoma

NCT00057954
View directory record Official record
Conditions
Lymphoma
Interventions
Extracorporeal Photopheresis, Pentostatin, Total body irradiation (TBI), Allogeneic bone marrow transplantation, Cyclosporin (CSA), Mycophenolate mofetil (MMF), Methotrexate (MTX)
Procedure · Drug · Radiation
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
19
States / cities
Aurora, Colorado • Boulder, Colorado • Colorado Springs, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Oct 19, 2026, 10:46 PM EDT
Completed Phase 3 Interventional

Assessing Screening Plus Brief Intervention's Resulting Efficacy (ASPIRE) to Stop Drug Use

NCT00876941
View directory record Official record
Conditions
Drug Usage, Drug Abuse, Drug Dependence
Interventions
Standard Brief Intervention, Enhanced Brief Intervention, Control: Information and Feedback
Behavioral
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Enrollment
589 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 2, 2014 · Synced Oct 19, 2026, 10:46 PM EDT
Terminated Phase 4 Interventional Results available

Conventional vs Bipolar SIJ RFA for Treatment of Sacroiliac Joint Pain

NCT05409443
View directory record Official record
Conditions
Sacroiliac Joint Complex, Low Back Pain
Interventions
Nimbus Sacroiliac Joint Radiofrequency Ablation (N-SIJRFA), Conventional Sacroiliac Joint Radiofrequency Ablation (C-SIJRFA)
Procedure
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 90 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
3
States / cities
Farmington, Utah • Salt Lake City, Utah • South Jordan, Utah
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 19, 2026, 10:46 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Successful Aging and Enrichment (SAGE)

NCT05128396
View directory record Official record
Conditions
Cognitive Health, Healthy Aging
Interventions
Cognitive Stimulation, Mindfulness training, Physical Activity, Control Group
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
65 Years and older
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Oct 19, 2026, 10:46 PM EDT
Recruiting Not applicable Interventional

Stratified Targeted Engagement From Primary Care to Physical Therapy (STEPPT)

NCT07290361
View directory record Official record
Conditions
Low Back Pain, Neck Pain
Interventions
Engagement of clinic leadership (System Intervention - Usual Care), Engagement of clinic leadership (System Intervention - STEPPT), Patient Registry (System Intervention - STEPPT), Delivery of Patient Education Materials (System Intervention - Usual Care), Delivery of Patient Education Materials (System Intervention - STEPPT), Referral Specialist Training (System Intervention - Usual Care), Patient Health Navigator Training (System Intervention - STEPPT), Care Navigation (System Intervention - STEPPT), Care navigation audit and feedback (System Intervention - STEPPT), Primary Care Provider training (Provider Intervention - STEPPT), Nurse/Medical Assistant Training (Provider Intervention - STEPPT), Provider feedback on PT referral and adherence (Provider Intervention - STEPPT), Patient education on spine pain condition (Patient Intervention - Usual Care), Patient education on spine pain condition (Patient Intervention - STEPPT), Patient Education on Physical Referral by Providers (Patient Intervention - Usual Care), Patient Education on Physical Referral by Providers (Patient Intervention - STEPPT), Electronic Patient Education on Physical Therapy Referral (Patient Intervention - STEPPT), Patient education on physical therapy referral by Referral Specialist (Patient Intervention - Usual Care), Patient education on physical therapy referral by Patient Health Navigator (Patient Intervention - STEPPT), Care Navigation (System Intervention - Usual Care), Monitoring of PT referral and adherence rates (System Intervention - STEPPT), Monitoring of PT referral and adherence rates (System intervention - Usual Care)
Behavioral
Lead sponsor
San Diego State University
Other
Eligibility
18 Years and older
Enrollment
17,587 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 19, 2026, 10:46 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

DeADT - Living Well With Prostate Cancer

NCT06199986
View directory record Official record
Conditions
Prostate Cancer
Interventions
ADT Order Check Attestation (Or), Provider Script (Sc)
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 26, 2025 · Synced Oct 19, 2026, 10:46 PM EDT
Completed Not applicable Interventional

Cervical and Upper Thoracic Mobilization and Manipulation for Mechanical Neck Pain

NCT02036905
View directory record Official record
Conditions
Neck Pain
Interventions
Cervical and thoracic mobilization, cervical and thoracic manipulation
Other
Lead sponsor
Youngstown State University
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
2
States / cities
Solon, Ohio • Havertown, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 26, 2016 · Synced Oct 19, 2026, 10:46 PM EDT
Completed Phase 1 Interventional

N2007-03: Vorinostat and 131-I MIBG in Treating Patients With Resistant or Relapsed Neuroblastoma

NCT01019850
View directory record Official record
Conditions
Neuroblastoma
Interventions
Vorinostat, 131- I Metaiodobenzylguanidine, Peripheral Blood Stem Cell Infusion, Filgrastim
Drug · Radiation · Procedure
Lead sponsor
New Approaches to Neuroblastoma Therapy Consortium
Other
Eligibility
2 Years to 30 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
12
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2023 · Synced Oct 19, 2026, 10:46 PM EDT
Active, not recruiting Phase 1 Interventional

Activated T Lymphocytes Expressing CARs, Relapsed CD19+ Malignancies Post-Allo HSCT(CARPASCIO)

NCT02050347
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma, B-Cell ALL, B-Cell CLL
Interventions
CD19.CAR-CD28Z T Cells - dose escalation 2, CD19.CAR-CD28Z T Cells - dose escalation 1
Genetic
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Not listed
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2030
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 19, 2026, 10:46 PM EDT
Completed Phase 1 Interventional

Shorter Course Tacrolimus After Nonmyeloablative, Related Donor BMT With High-dose Posttransplantation Cyclophosphamide

NCT01342289
View directory record Official record
Conditions
Hodgkin's Lymphoma, Leukemia, Myelodysplastic Syndrome(MDS), Multiple Myeloma, Non Hodgkin's Lymphoma
Interventions
Cyclophosphamide, Fludarabine, Total body irradiation, Mycophenolate Mofetil, Tacrolimus 60, Tacrolimus 90, Tacrolimus 120, Bone marrow transplant
Drug · Radiation · Biological
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
6 Months to 75 Years
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 17, 2018 · Synced Oct 19, 2026, 10:46 PM EDT
Completed Not applicable Interventional Results available

Minnesota Community-Based Cognitive Training in Early Psychosis

NCT03079024
View directory record Official record
Conditions
Schizophrenia, Psychosis, Schizoaffective Disorder, Schizophreniform Disorders, Psychosis NOS, Depression Psychotic Feature, Bipolar Disorder With Psychotic Features, Unspecified Psychosis
Interventions
Targeted Cognitive Training, General Cognitive Exercises, Coordinated Specialty Care for First Episode Psychosis
Device · Other
Lead sponsor
University of Minnesota
Other
Eligibility
16 Years to 35 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 23, 2025 · Synced Oct 19, 2026, 10:46 PM EDT
Recruiting Phase 2 Interventional

A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Subjects With VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome

NCT05027945
View directory record Official record
Conditions
Immunodeficiency, Hematopoietic Stem Cell Transplantation
Interventions
Allogeneic HSCT, Busulfan test dose, Mycophenolate mofetil (MMF), Tacrolimus, Busulfan, Total Body Irradiation (TBI), Fludarabine, Cyclophosphamide (CY), Post-Transplant Cyclophosphamide (PTCY)
Procedure · Drug · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 75 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 19, 2026, 10:46 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells

NCT01050764
View directory record Official record
Conditions
Leukemia, Acute, Chronic Myelogenous Leukemia (CML), Myelodysplastic Syndrome (MDS), Non-Hodgkin Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Acute Myelogenous Leukemia (AML), Acute Lymphoblastic Leukemia (ALL)
Interventions
Regulatory T-cells, Conventional T-cells, Melphalan, Thiotepa, Fludarabine, Anti-thymocyte globulin, rabbit, CliniMACS CD34 Reagent System
Drug · Device
Lead sponsor
Everett Meyer
Other
Eligibility
Up to 60 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 27, 2018 · Synced Oct 19, 2026, 10:46 PM EDT
Completed Phase 1 Interventional

Velcade and Lenalidomide in Patients With Relapsed AML and MDS After Allogeneic Stem Cell Transplantation

NCT02312102
View directory record Official record
Conditions
Myelodysplastic Syndrome, Acute Myeloid Leukemia
Interventions
Lenalidomide, Velcade
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 16, 2026 · Synced Oct 19, 2026, 10:46 PM EDT
Completed Phase 1 Interventional

Administration of Virus-Specific Cytotoxic T-Lymphocytes

NCT00590083
View directory record Official record
Conditions
Adenovirus Infection
Interventions
CTL administration
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Not listed
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 19, 2014 · Synced Oct 19, 2026, 10:46 PM EDT
Completed Phase 1 Interventional

Bortezomib in Treating Patients With Multiple Myeloma Who Have Undergone an Autologous Peripheral Blood Stem Cell Transplant

NCT00288028
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
bortezomib
Drug
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 19, 2013 · Synced Oct 19, 2026, 10:46 PM EDT
Completed Early Phase 1 Interventional

Sirolimus, Tacrolimus and Short Course Methotrexate for Prevention of Acute GVHD in Recipients of Mismatched Unrelated Donor Allogeneic Stem Cell Transplantation

NCT00612274
View directory record Official record
Conditions
Stem Cell Transplantation
Interventions
tacrolimus, Sirolimus, Methotrexate
Drug
Lead sponsor
Yale University
Other
Eligibility
16 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 30, 2016 · Synced Oct 19, 2026, 10:46 PM EDT
Completed Phase 2 Interventional

Safety and Preliminary Efficacy Study of NeoFuse in Subjects Undergoing Multi-Level Anterior Cervical Discectomy

NCT01097486
View directory record Official record
Conditions
Cervical Degenerative Disc Disease, Degenerative Spondylolisthesis, Spinal Stenosis
Interventions
NeoFuse, Allograft
Biological · Procedure
Lead sponsor
Mesoblast, Ltd.
Industry
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
8
States / cities
Sacramento, California • Santa Monica, California • Denver, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2019 · Synced Oct 19, 2026, 10:46 PM EDT
Not listed Phase 1Phase 2 Interventional

Standard Process 21 Day Purification Program Project

NCT00724217
View directory record Official record
Conditions
Hyperlipidemia
Interventions
Standard Process 21 Day Purification Program (SPPP)
Other
Lead sponsor
Logan College of Chiropractic
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Chesterfield, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 29, 2008 · Synced Oct 19, 2026, 10:46 PM EDT
Completed Phase 1 Interventional

T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer

NCT00602693
View directory record Official record
Conditions
Leukemia, Lymphoma, Multiple Myeloma, Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions
umbilical cord blood transplantation, Allopurinol, fludarabine phosphate, Cyclophosphamide, Total body irradiation, Treg infusion, Sirolimus
Biological · Drug · Radiation
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years to 75 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 2, 2017 · Synced Oct 19, 2026, 10:46 PM EDT
Completed Phase 1 Interventional

Decitabine Maintenance for Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS) Post Transplant

NCT00986804
View directory record Official record
Conditions
Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
Interventions
Decitabine
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 15, 2016 · Synced Oct 19, 2026, 10:46 PM EDT